Cellino

🌟We're #hiring a new Bioengineer in Cambridge, Massachusetts. Apply today or share this post with your network! 💫

What if we could help patients regain lost function with personalized cell and tissue replacements? 🚀 That’s the bold vision behind Cellino's recently collaboration with Matricelf. To dive deeper, we sat down with Tal Dvir, Ph.D., Co-Founder and Chief Scientific Officer of Matricelf, to discuss why this collaboration is a game-changer, how regenerative tissue therapies could transform lives, and—most importantly—what this could mean for spinal cord injury patients and their quality of life. 💡 Regenerative medicine isn’t just about innovation—it’s about people. With advances like this, we’re taking real steps toward therapies that restore both function and hope. 🔗 Check out the full conversation below! 👇 #RegenerativeMedicine #Biotech #Innovation #PatientsFirst #SpinalCordInjury

🚀 We’re thrilled to share that Rebecca "Becky" Kusko, PhD, Chief of Staff & Head of Strategy at Cellino, will be attending the J.P. Morgan Boston Innovation Economy Summit on Wednesday, March 26 in #Boston! We're looking forward to the incredible lineup of speakers, including George Church, PhD, Founding Core Faculty & Lead, Synthetic Biology at the Wyss Institute at Harvard University, Steve Papa, Founder & CEO of Parallel Wireless, and Amy Villeneuve, Board Member and former President & COO of Amazon Robotics, as they explore biotech, AI, and the emerging technologies that define the spirit of innovation in our city. 🏙️ Heading to the Summit? Follow Cellino for updates and connect with Becky to learn more about Cellino’s #AI-driven #biomanufacturing platform and how we’re expanding access to personalized regenerative medicine for patients. #JPMorgan #BostonInnovation #DeepTech #Biomanufacturing #RegenMed #PersonalizedMedicine #YourCellsYourCure #Cellino

🧬 Thank you Longevity.Technology and Danny Sullivan for highlighting our collaboration with Matricelf in advancing personalized regenerative medicine! 🚀 We’re committed to building the future of #AI-driven #biomanufacturing, and this collaboration represents a major step forward in developing patient-specific neural tissues for spinal cord injury treatment. “Aging and injury both stem from the body’s diminishing ability to self-repair—this breakthrough enables personalized, patient-derived iPSCs to restore function once thought irreversible. For spinal cord injury patients, this could one day mean walking again," said Cellino CEO & Co-Founder Nabiha Saklayen. 📄 Read the full article: https://lnkd.in/eYJ_SGKV Cellino has manufactured and delivered iPSC lines from four donors to Matricelf, supporting the creation of engineered neural tissues that eliminate the need for immunosuppression and transform how we develop treatments for #neurodegenerative diseases. #RegenerativeMedicine #iPSCs #AI #CellTherapy #SpinalCordInjury #SCI #PatientsFirst #Collaboration #Innovation #YourCellsYourCure #Cellino

🔬 Join Cellino’s SVP of Therapeutics Development, Chris Gemmiti, Ph.D., at "Crossing The Chasm: Navigating Innovation and Access to Advanced Therapies," held at the Broad Institute of MIT and Harvard on March 18 from 2:00 PM to 8:00 PM ET. Chris Gemmiti, Ph.D. will be speaking on the panel, "Scaling the Summit of Access: Building Infrastructure for Community-Level Therapy Delivery," focusing on the important steps needed to advance autologous iPSC treatment for chronic degenerative conditions. 🎤 Chris will be joined by: Joe DePinto, Head of Cell, Gene, and Advanced Therapies, McKesson Sadik Kassim, PhD, CSO/CTO, Danaher Corporation Phil St-Cyr, Market Access/HEOR Expert Ed Saltzman, Senior Strategic Advisor, Lumanity This event will bring together leaders across science, policy, and industry to address the challenges and opportunities in delivering personalized therapies at scale. 100% of proceeds from ticket sales and sponsorships will directly support the Damon Runyon Cancer Research Foundation and its mission to fund high-risk, high-reward cancer research. 👉 Be part of the conversation and learn more: https://lnkd.in/gnTERB5D #DamonRunyonFoundation #CancerResearch #LifeSciences #DeepTech #Innovation #Healthcare #Biomanufacturing #RegenMed #YourCellsYourCure #Cellino

👏👏 We're incredibly proud of our very own Nabiha Saklayen, CEO & Co-Founder, and Marinna Madrid, PhD, Co-Founder & Chief Product Officer, for being named to Inc. Magazine’s 2025 Female Founders 500 list! Their leadership in #deeptech and #biomedicine is advancing the future of personalized regenerative medicine, accelerating treatment options for Parkinson’s, spinal cord injury, and other chronic degenerative conditions. Check out their profiles and learn more about Cellino below. Nabiha Saklayen Inc. Founder Profile: 🔗 https://lnkd.in/gEvZaghT     Marinna Madrid Inc. Founder Profile: 🔗  https://lnkd.in/g4XsQChH You can view the full list of honorees here: https://lnkd.in/gEb9rQb9 #IncMagazine #FemaleFounders500 #Biotech #Parkinsons #SCI #Innovation #PersonalizedMedicine #RegenMed #YourCellsYourCure #Cellino

🌍 At Cellino, we are committed to making personalized regenerative medicine scalable and accessible to all patients. Our collaboration with Matricelf is a testament to how international partnerships can drive innovation and expand access to life-changing therapies. Together, we are combining Cellino’s autonomous iPSC manufacturing technology with Matricelf’s advanced tissue engineering to push the boundaries of patient-specific regenerative medicines for spinal cord injury. This collaboration is breaking new ground in scalable, personalized treatments—bringing transformative therapies closer to patients who need them most. 🔗📘 Learn more by checking out the full press release, featuring insights from Cellino Co-Founder & Chief Product Officer Marinna Madrid, PhD and Matricelf CEO Gil Hakim: https://lnkd.in/ePC-Z2PR #RegenerativeMedicine #iPSCs #AI #CellTherapy #SpinalCordInjury #PatientsFirst #Collaboration #Innovation

At Cellino, we believe the future of regenerative medicine lies in scalable, patient-specific therapies—and we’re excited to share an exclusive discussion between Marinna Madrid, PhD, Co-Founder & Chief Product Officer at Cellino, and Tamar Harel-Adar, Ph.D., VP of R&D at Matricelf where they dive deep into our exciting collaboration.  🎥✨ Marinna explains how Cellino’s optical bioprocessing technology is transforming iPSC manufacturing with AI-driven automation for unmatched precision and scalability. Tamar shares how Matricelf’s double autologous approach, combining Cellino-generated iPSCs with Matricelf's unique autologous hydrogel, is advancing personalized neural tissue replacements without immunosuppression. Together, we’re tackling one of regenerative medicine’s biggest challenges: scalability. How do we make these groundbreaking therapies accessible to the patients who need them? 🔗 Watch the full conversation to learn how AI, automation, and regenerative medicine are converging to pave the path to brighter futures for spinal cord injury patients. Watch at: https://lnkd.in/eTC_nRYH #RegenerativeMedicine #iPSCs #SpinalCordInjury #PatientsFirst #Collaboration #Innovation #CellTherapy #YourCellsYourCure

👏 Congratulations to Nabiha Saklayen, our CEO & Co-Founder, and Marinna Madrid, PhD, our Co-Founder & Chief Product Officer, on being recognized in Inc. Magazine’s 2025 Female Founders 500! This recognition highlights their visionary leadership and commitment to advancing patient access to personalized regenerative medicines. Our innovative #AI-driven optical bioprocess brings autonomy to traditionally manual manufacturing processes, enabling the scalable production of patient-specific cells, tissues, and organs. Cellino is accelerating patient access to treatment options for Parkinson’s, spinal cord injury, and other chronic degenerative conditions, with the goal of making personalized regenerative therapies available affordable and at scale. 🏆 Read the full article: https://lnkd.in/gEb9rQb9 🔬 Learn more about our technology: https://lnkd.in/gb-9tnAB We're so proud to see Nabiha, Marinna, and so many inspiring founders celebrated on this year's list! #IncMagazine #FemaleFounders #Biotech #DeepTech #Innovation #PersonalizedMedicine #RegenMed #YourCellsYourCure #Cellino

🚀🚀We’re thrilled to announce our international collaboration with Matricelf to scale personalized spinal cord injury treatments using Cellino’s Nebula™ technology and Matricelf’s breakthrough regenerative approach! Cellino successfully manufactured and delivered autologous iPSC lines from four donors to Matricelf, which has now transformed them into functional neural tissues with synchronized electrical activity, demonstrating the high quality of Cellino’s iPSCs! ⚡🧠 By combining Cellino’s AI-driven iPSC biomanufacturing with Matricelf’s 3D differentiation process, this collaboration is advancing the scalability of personalized spinal cord therapies for patients who currently have limited treatment options. We are especially grateful to the incredible Matricelf team—Tamar Harel-Adar, Gil Hakim, and Tal Dvir—for their pioneering work in neural tissue engineering. Their dedication is driving the future of scalable, patient-specific regenerative therapies. 📄Read the full release: https://lnkd.in/ePC-Z2PR #Cellino #Matricelf #RegenerativeMedicine #iPSC #Biomanufacturing #AI #SpinalCordInjury